TransCode Therapeutics Total Assets

The latest total assets for RNAZ is $160B as of March 2026. That compares with $13B in the prior-year period — up 1091.2% year over year. Investors often review this figure alongside TransCode Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, RNAZ's total assets moved from $13B to $160B — a 1091.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in TransCode Therapeutics's operating scale or balance-sheet position.

A total assets figure of $160B for RNAZ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RNAZ's total assets ($160B), review year-over-year change from $13B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack TransCode Therapeutics's total assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.